As shown in Fig. 7c and Supplementary Fig. 11a, c, treatment with the CM derived from LNMAT1 cells significantly increased the expression of specific M2 marker (CD206 and CD163) but decreased the expression of M1 markers (HLA-DR and CD86) compared with similar treatment in the vector cells, which provides further evidence that LNMAT1 overexpression in cancer cells induces TAMs activation. Here, CD86 is linked to cancer.